We conducted a retrospective chart review of human immunodeficiency virus (HIV)-infected patients who died in 1995 and in 1999-2000. We found an increase in the proportion of patients who died from an illness that was not related to acquired immunodeficiency syndrome (AIDS). Although there was a decrease in the prevalence of AIDS-defining illnesses, 185% of patients died with CD4 counts of !200 cells/mL. The leading cause of death was Pneumocystis carinii pneumonia (PCP). Nonadherence to therapy and new diagnosis of HIV infection were the leading reasons why patients were not receiving antiretroviral therapy. The leading causes of non-AIDS-related deaths in 1999-2000 were non-AIDS-defining infections and end-stage liver disease. At our hospital, PCP remains an important cause of death in the highly active antiretroviral therapy (HAART) era, possibly because 150% of HIV-infected patients who died were not receiving HAART. AIDSdefining illnesses continue to be a major cause of mortality in the HAART era in populations where access to care and adherence to HAART is limited.
whereas a study from France suggested that 50% of deaths in the HAART era continue to be due to AIDSdefining illnesses [7] . Some studies of HIV-infected persons suggest that the proportion of non-AIDS-related deaths has increased in the HAART era [6, [8] [9] [10] , whereas other studies have found no such changes [11, 12] . An increasing proportion of deaths due to liver disease have been noted in some descriptive and cohort-based mortality studies but not in others [13] [14] [15] . We conducted a retrospective chart review of patients who died at Parkland Memorial Hospital in Dallas, Texas, to evaluate specific causes of death in 1995 and in 1999-2000, reflecting the deaths before introduction of HAART and several years after widespread use of HAART began.
view of all HIV-infected adults who died at Parkland Memorial Hospital in 1995 and 1999-2000 was conducted. International Classification of Diseases, Ninth Revision, codes were used to identify those with documented HIV infection.
Data collection. Data from medical records were collected regarding each patient's demographic characteristics, HIV risk factors, liver disease risk factors, CD4 cell count, and HIV load, as well as antiretroviral therapy and Pneumocystis carinii pneumonia (PCP) prophylaxis received. We determined the cause of death by a chart review on the basis of clinical, laboratory, and microbiologic data. Autopsy reports, when available, were also used to determine the cause of death. An attempt was made to assign one primary cause of death to each case. For patients who had several possible causes of death, 3 investigators (M.J., D.S., and D.B.) reviewed the records, including available autopsy reports, to determine the probable primary cause of death. Other possible causes of death were considered to be contributing causes of death.
Definitions. In cases in which no autopsy was performed, we used the following definitions to determine the primary cause of death. Death due to end-stage liver disease (ESLD) was defined as death of a patient with underlying liver disease and у1 of the following conditions: coagulopathy, bleeding esophageal varices, hepatic encephalopathy, hepatorenal syndrome, or spontaneous bacterial peritonitis. Death due to definite PCP was defined as death of a patient with respiratory failure and a positive result of a PCP direct fluorescence antibody test of sputum. Death due to probable PCP was defined as death of a patient with respiratory failure and у2 of the following conditions: hypoxia, compatible chest radiograph findings demonstrating an interstitial infiltrate, or an elevated lactate dehydrogenase level without microbiologic confirmation of another infectious process. Death due to bacterial pneumonia was defined as death of a patient with either compatible chest radiograph findings (patchy alveolar infiltrates or consolidation) and a blood culture result positive for a bacterial pathogen or compatible chest radiograph findings and 2 of the 3 following conditions: a sputum culture result revealing a pathogen known to cause bacterial pneumonia, fever (temperature of 138ЊC), or an elevated level of polymorphonuclear leukocytes as determined by a differential WBC count of peripheral blood. Death due to malignancy was defined as death of a patient with a biopsy-proven malignancy and without another probable cause of death. Death due to sepsis was defined as death of a patient with a blood culture positive for a bacterial pathogen but without bacterial pneumonia and/or with evident refractory hypotension that required vasopressor therapy in the absence of another cause of refractory hypotension. Death due to cytomegalovirus (CMV) infection was defined as death of a patient with biopsy-proven or culture-proven end-stage organ disease due to CMV. For patients whose death was more likely due to other causes, CMV infection was considered a contributing cause. Finally, a patient was considered to have died of Mycobacterium avium-intracellulare (MAI) infection if this infection was proven by culture and no other cause of death was likely.
Other terms used in this study were defined as follows. Death due to an AIDS-defining illness was defined as death attributable to one of the Centers for Disease Control and Prevention (CDC) category C diseases [16] . Probable immunodeficiencyrelated diseases included CDC category B diseases or diseases that we considered to probably be CDC category C conditions but for which there was insufficient data for a conclusive determination. These diseases include undiagnosed CNS mass (i.e., probable toxoplasmosis or primary brain lymphoma) and bacterial pneumonia due to Streptococcus pneumoniae or Haemophilus influenzae (i.e., probable recurrent pneumonia). Death due to HIV-associated diseases was defined as death of a patient due to an AIDS-defining illness or a probable immunodeficiency-related disease.
The outpatient HIV clinic database was searched to determine the number of visits made by each patient in the 12 months before death. A patient was considered to have an HIVinfection primary care provider if he or she had made у3 visits in the past year or if HIV-infection-specific treatment had been initiated. Pharmacy data were reviewed to verify that the patient was receiving HAART (defined as у3 antiretroviral drugs belonging to у2 classes, the prescriptions for which were refilled in the 3 months before death) or had an undetectable HIV load (defined as !400 HIV RNA copies/mL) in the 2 months before death. Patients were considered to have been receiving PCP prophylaxis if pharmacy records showed prescription refills during the 2 months before death for trimethoprimsulfamethoxazole, pentamidine, dapsone, or atovaquone. Because pharmacy data were not available for 1995, PCP prophylaxis data were determined by chart review. Data related profile of the study population are presented in table 1. The 2 groups were similar with respect to age and sex, but HIV risk factors were different in period 1 than they were in period 2, with men who have sex with men being more common in period 1. In period 1, 54 (48%) of 112 patients were of black or Hispanic origin, compared with 53 (60%) of 88 in period 2 ( ). No patients from period 1 received HAART, P p .09 which was unavailable in 1995. Despite widespread availability after 1995, only 48% of patients from period 2 received HAART, and 13 patients had HIV RNA levels of !400 copies/mL. The median CD4 cell counts (measured within 8 months of the time of death) were similar in both groups. CD4 cell counts were not available for 14 (13%) of 112 patients in period 1 and 4 (5%) of 88 patients in period 2.
A comparison of the leading causes of death in each group is shown in table 2. A trend toward a decrease in AIDS-defining illnesses as cause of death occurred. A significant decrease in deaths due to HIV-associated diseases occurred between period 1 and period 2. The proportion of patients who died as a result of PCP (probable or definite) did not change between the 2 periods. There were no deaths due to CMV, MAI, or toxoplasmosis in period 2. Because the proportion of deaths attributable to HIV-associated illnesses decreased from period 1 to period 2, non-AIDS-related illnesses increased. The leading non-AIDS-related causes of death in both time periods were infections and ESLD. Four patients in period 2 died of intracerebral hemorrhages (2 parenchymal and 2 subarachnoid).
Other causes of death due to non-AIDS-related illnesses did not differ between the 2 time periods. Bacterial pneumonia and sepsis were the most common death were examined for both periods. In period 1, 7 patients (6%) were considered to have pneumonia that did not meet the case definition of PCP contributing to death, compared with none in period 2 ( ). No significant difference was P p .02 seen in other contributing causes of death.
Analysis stratified by receipt of HAART and CD4 cell count. Analysis of deaths stratified by patients receipt of HAART, presented in table 3, is limited to period 2, when HAART was available. Forty-two (48%) of 88 patients in period 2 were receiving HAART. The reasons why patients were not receiving HAART were the following: 18 (39%) of 46 patients were not adherent to regimens, 12 patients (26%) had a new diagnosis of HIV infection within 6 months of death, 5 patients (11%) could not tolerate HAART because of underlying liver disease, 5 patients (11%) had unavailable data, 4 patients (9%) were unable to tolerate HAART because of side effects or progression of AIDS, and 2 patients (4%) were lost to follow-up (one of these patients had HIV infection diagnosed within 9 months of death).
Patients who received HAART had a median CD4 cell count (43 cells/mL) similar to those who did not receive HAART (30 cells/mL). Patients receiving HAART were more frequently receiving PCP prophylaxis and less frequently had a CD4 cell count of !200 cells/mL. A significantly higher proportion of patients who were receiving HAART died of non-AIDS-related illnesses. No patients receiving HAART died of the following AIDS-defining illnesses: Cryptococcus infection, histoplasmosis, or Kaposi sarcoma. No significant differences existed between Figure 1 . Leading cause of death, by CD4 cell count. All comparisons were made by Fisher's exact test. Definitions of causes of death are as follows: "sepsis," nonpneumonia causes of sepsis; "malignancies," all AIDS-defining or non-AIDS-related neoplastic causes of death; and "pneumonia," all bacterial pneumonias, including those due to Streptococcus pneumoniae and Haemophilus influenzae. ESLD, end-stage liver disease; PCP, Pneumocystis carinii pneumonia. the 2 groups with respect to other causes of death. The leading causes of death in patients receiving HAART were bacterial infections and ESLD, whereas, in those patients who were not receiving HAART, the leading cause of death was PCP.
Stratification of patients by CD4 cell count of у200 cells/ mL or !200 cells/mL, regardless of period, revealed 161 patients with a CD4 cell count of !200 cells/mL and 21 patients with a CD4 cell count of у200 cells/mL. As shown in figure 1, 9 (43%) of 21 patients with a CD4 cell count of у200 cells/mL died of ESLD, compared with 13 (8%) of 161 who had a CD4 cell count of !200 cells/mL ( ). PCP was the primary cause P ! .001 of death in 33 patients (20%) who had a CD4 cell count of !200 cells/mL, whereas no PCP-related deaths occurred in patients who had a CD4 cell count of у200 cells/mL ( ). P p .02 Liver disease. A similar proportion of patients in period 1 were hepatitis C virus (HCV) antibody positive, were hepatitis B surface antigen (HBsAg) positive, had a history of heavy alcohol intake, had underlying liver disease, or had elevated serum alanine aminotransferase levels at admission, compared with patients from period 2 (data not shown). However, when stratified by CD4 cell count, as shown in table 4, each of the following was more common in patients with a CD4 cell count of у200 cells/mL: HCV or HBsAg positivity, history of heavy alcohol intake, and evidence of liver disease at admission. A significantly higher proportion of ESLD deaths occurred in patients with higher CD4 cell counts regardless of year of death (data not shown). Further analysis of all patients who died of ESLD ( ) showed that, in 13 (59%) of 22 patients, HCV n p 22 contributed to liver disease; in 9 (41%) of 22, liver disease was related to hepatitis B virus; and, in 12 (55%) of 22, alcohol use contributed to liver disease. Eleven (58%) of 19 patients with ESLD had both HCV or HBsAg positivity and concomitant heavy alcohol intake.
DISCUSSION
Among HIV-infected persons hospitalized at Parkland Memorial Hospital, HAART has affected cause-specific HIVrelated mortality only modestly. Nationwide, the leading causes of death before 1996 were PCP, MAI, CMV, and bacterial pneumonia [17] . In developed countries, HAART and prophylaxis for opportunistic infections have markedly reduced opportunistic infection-related deaths [2, 6, 9] . Yet, at our safety-net hospital, which provides a Ryan White-funded, state-of-theart HIV outpatient clinic and a National Institutes of Healthsponsored AIDS clinical trials unit, the HAART era brought a less-marked change. The proportion of deaths due to PCP was the same in 1999-2000 as it was in 1995. This observation differs from numerous published studies documenting a reduction in mortality from PCP [2, 8, [18] [19] [20] . Several factors may explain why PCP remains a leading cause of death in our patient population. First, despite the availability of HAART, the majority (89%) of patients in 1999-2000 died of AIDS (as defined by a CD4 cell count of !200 cells/mL). Second, almost one-half of patients who died in 1999-2000 were not receiving HAART because of nonadherence to medications or new diagnosis of HIV infection. Nonadherence to HAART also appeared to be associated with nonadherence to PCP prophylaxis in this resource-limited patient population. Longitudinal data show the risk of death is significantly decreased in patients receiving primary PCP prophylaxis [3] . A significant increase in the proportion of non-AIDS-related deaths did occur between 1995 and 1999-2000. Unlike other studies that show an increase in the proportion of deaths due to liver disease [10, 15] , we did not find a significant change in the proportion of deaths due to this cause. Like other studies [6, 12] , we did not see an increase in the proportion of deaths due to non-AIDS-defining infections. However, these 2 etiologies were the most common non-AIDS-related causes of death in both time periods. We did see an increase in intracerebral hemorrhages not related to an underlying CNS lesion. Changes in diagnostic evaluation may account for these differences.
Comparison of patients who were receiving HAART to those who were not revealed a decrease in HIV-associated deaths and an increase in non-AIDS-related deaths. Although we did not see a significant decrease in AIDS-defining illnesses in our patients receiving HAART, other studies have shown that use of HAART does decrease the number of deaths due to AIDSdefining illnesses [1, 3, 4] . HAART has also been associated with a decrease in disease progression and death in patients with CD4 cell counts of !200 cells/mL [21, 22] . Seventy-seven percent of our patients receiving HAART had CD4 cell counts of !200 cells/mL, but 60% of these deaths were due to non-AIDS-related diseases. Our small sample size may have precluded detection of significant differences in specific causes of death. Despite this limitation, some interesting trends were noted. Patients not receiving HAART more frequently died of PCP, which was also the leading cause of death in patients in the pre-HAART era. However, the patients who died in 1999-2000 while receiving HAART more frequently died of ESLD. Non-AIDS-defining infections in patients receiving HAART were similar to those in patients who were not receiving HAART. Larger cohort studies are needed to determine the impact of HAART on deaths due to liver disease and other causes.
Many of the patients not receiving HAART were of ethnic minorities. Nine (75%) of 12 patients with newly diagnosed HIV infection and 12 (67%) of 18 nonadherent patients were black or Hispanic. Deaths among HIV-infected minorities increased at our hospital from 48% in 1995 to 61% in 1999-2000. National surveys show that the incidence of AIDS (per 100,000 persons) in 2000 was 3 times higher among Hispanic persons (30.4) and 9 times higher among black persons (74.2) than it was among white persons (7.9) [23] . Minorities may have limited access to medical care for economic, social, and cultural reasons. Lower socioeconomic status has been associated with a decreased duration of survival in patients with AIDS [24] . Efforts targeted at improving early diagnosis and adherence to medical therapy may decrease the mortality rate in this population.
Our data demonstrate that the leading cause of death in patients who died with a CD4 cell count of у200 cells/mL was ESLD. The finding that 10% of our patients died with a CD4 cell count of у200 cells/mL in both 1995 and 1999-2000 differs from the findings of a study from Boston in which the proportion of patients who died with a CD4 cell count of у200 cells/mL increased from 2.8% in 1996 to 18.2% in 1998-1999 [15] . A possible explanation for the increasing deaths due to ESLD from the Boston study may be the higher proportion of Boston pa-tients dying with CD4 cell counts of у200 cells/mL. Because the proportion of patients who died with a CD4 cell count of у200 cells/mL did not change over time in our study, we did not observe an increase in the proportion of deaths due to ESLD.
Our study is limited to inpatient deaths, and, therefore, we cannot calculate mortality rates or evaluate a causal association between HAART and HIV-associated deaths. As in any retrospective study, we cannot exclude bias, but we used consistent definitions to minimize potential bias. Although the case definition of probable PCP may have misclassified a few cases in 1995, the increase in definite PCP in 1999-2000 suggests that PCP remains an important cause of death in our population. Larger prospective cohort studies in the HAART era are needed to define the impact of HAART on the changing pattern of deaths.
In our study, a trend toward a decrease in deaths due to AIDS-defining illness did occur in the HAART era compared with the pre-HAART era. However, PCP still remains an important cause of death. The leading non-AIDS-related deaths were due to non-AIDS-defining infections and ESLD in both time periods. In the subset of patients with CD4 cell counts of у200 cells/mL, ESLD was the leading cause of death. Strategies for the prevention and treatment of alcohol addiction, hepatitis B virus infection, and HCV infection may have an important impact on deaths due to ESLD in HIV-infected patients receiving HAART. The majority of patients who died in the HAART era had a CD4 cell count !200 cells/mL, and almost one-half of these patients who died were not receiving HAART at the time of death. Strategies to improve early diagnosis and maximize treatment adherence may lead to improved survival in high-risk populations.
